Aller au contenu principal
Fermer
  2. Aide
  2. Aide

FDA autorise Dupixent de Sanofi chez enfants 2-11 ans atteints d’urticaire chronique spontanée
information fournie par Reuters 22/04/2026 à 23:30

* FDA autorise Dupixent (dupilumab) de Sanofi, co-développé avec Regeneron, chez enfants de 2 à 11 ans atteints d’urticaire chronique spontanée non contrôlée malgré antihistaminiques H1. * Extension indication aux États-Unis, Dupixent déjà indiqué dans cette pathologie chez adultes, adolescents de 12 ans et plus. * Décision fondée principalement sur programme LIBERTY-CUPID, réduction significative prurit, activité urticarienne à 24 semaines versus placebo observée dans études de phase 3 chez adultes, adolescents. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604221730PRIMZONEFULLFEED1001177421) on April 22, 2026, and is solely responsible for the information contained therein.

(C) Copyright 2026 - Public Technologies (PUBT)

Valeurs associées

SANOFI
80,780 EUR Euronext Paris -0,30%
© 2026 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.
Chargement...

Pages les plus populaires

L'offre BoursoBank